Mara B. Antonoff, MD, FACS, of the University of Texas MD Anderson Cancer Center, joined Lung Cancers Today to discuss what could be on the horizon for surgery in stage IV lung cancer during the 61st Annual Meeting of the Society of Thoracic Surgeons (STS) in Los Angeles. “I’m certainly hopeful that we can do some quality-of-life studies and some investigations looking at patient-reported outcomes,” Dr. Antonoff said. ...

Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
The bispecific antibody, which recently received FDA accelerated approval, showed a response rate of 29% in NSCLC.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The recommendation is based on results from the phase 3 ADRIATIC trial.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
The CHMP positive opinion is supported by results from the phase 3 PALOMA-3 study.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Pending discussions with the FDA, officials say there are plans to submit for regulatory approval in the second half of 2025.
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
Advertisement